Business
Big Pharma Seeks Innovation in China Amid Patent Cliff
Western biopharma companies are increasingly sourcing innovation from China as the patent cliff looms, driving multibillion-dollar deals. This shift is driven by the need to find new drugs and avoid the financial impact of expiring patents.
Coverage timeline — 1 article
CNBC
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
2026-10-02 11:18 UTC